Skip to main content
. 2023 Jun 3;23:416. doi: 10.1186/s12884-023-05723-1

Table 2.

Hypertension Treatment Status, Overall and By Pregnancy Status

Variables Overall
(N = 5972)
Not Pregnant
(N = 5860)
Pregnant
(N = 112)
P value
Walk-in Treatment [n (%)] 2503 (41.9%) 2467 (42.1%) 36 (32.1%) 0.03
Drug Class [n (%)] < 0.001
    Calcium Channel Blockers 1871 (74.8%) 1853 (75.1%) 18 (50.0%)
     ACE/ARB/Diuretics 339 (13.5%) 336 (13.6%) 3 (8.3%)
     Beta Blockers 13 (0.5%) 13 (0.5%) 0 (0%)
     Aspirin 20 (0.8%) 20 (0.8%) 0 (0%)
     Methyldopa/Other 260 (10.4%) 245 (4.2%) 15 (41.7%)
Walk-out Treatment [n (%)]º 5319 (89.1%) 5248 (89.6%) 71 (63.4%) < 0.001
Drug Class [n (%)]
     Calcium Channel Blockers 4998 (94.0%) 4953 (94.4%) 45 (63.4%)
     ACE/ARB/Diuretics 1295 (24.3%) 1284 (24.5%) 11 (15.5%)
     Beta Blockers 5 (0.09%) 5 (0.1%) 0 (0%)
     Aspirin 6 (0.1%) 6 (0.1%) 0 (0%)
     Methyldopa/Other 114 (2.1%) 94 (1.8%) 20 (28.2%)
New Treatment 3253 (54.5%) 3208 (54.7%) 45 (40.2%)†
No Treatment 216 (3.6%) 185 (3.2%) 31 (27.7%)
Stopped Treatment 315 (5.3%) 305 (5.2%) 10 (8.9%)
Continued/Altered Treatment 2503 (36.6%) 2162 (36.9%) 26 (23.2%)†

oout of 8 pregnant women, 3 were prescribed ARB and 5 were prescribed diuretics. †4 previously unmedicated pregnant patients were prescribed contraindicated medications; 4 previously medicated patients were prescribed contraindicated medications; walk-in treatment and walk-out treatment rates are the rates at the start and at the end of patients’ baseline visits respectively